Research studies in the Open Payments record

139,921 studies have research funding reported against them. Being named on a study as a principal investigator is reported separately from being paid.

Studies

50 of 139,921

201603149 No ClinicalTrials.gov identifier reported
2016-1378-Anton No ClinicalTrials.gov identifier reported
2016-1652 Keshavarzian No ClinicalTrials.gov identifier reported
2016-2007 Grant No ClinicalTrials.gov identifier reported
2016 Aspire Breast Cancer A Multicenter Phase III Trial of Anastrozole Palbociclib Trastuzumab and Pertuzumab in Hrpositive Her2positive Metastatic Breast Cancer No ClinicalTrials.gov identifier reported
2016 Aspire Breast Cancer A Multicenter Phase III Trial of Anastrozole Palbociclib Trastuzumab and Pertuzumab in Hrpositive Her2positive Metastatic Breast Cancer No ClinicalTrials.gov identifier reported
2016 Aspire Breast Cancer A Phase Ib Trial of Fulvestrant Palbociclib Cdk46 Inhibitor and Erdafitinib Jnj42756493 Panfgfr Tyrosine Kinase Inhibitor in Erher2fgframplified Metastatic Breast Cancer MBC No ClinicalTrials.gov identifier reported
2016 Aspire Breast Cancer A Phase Ib Trial of Fulvestrant Palbociclib Cdk46 Inhibitor and Erdafitinib Jnj42756493 Panfgfr Tyrosine Kinase Inhibitor in Erher2fgframplified Metastatic Breast Cancer MBC No ClinicalTrials.gov identifier reported
2016 Aspire Breast Cancer Phase Ib II Openlabel Single Arm Study to Evaluate Safety and Efficacy of Ont380 in Combination With Palbociclib and Letrozole in Patients With Hormone Receptor Positive and Her2positive Metastatic Breast Cancer No ClinicalTrials.gov identifier reported
2016 Aspire Breast Cancer Phase Ib II Openlabel Single Arm Study to Evaluate Safety and Efficacy of Ont380 in Combination With Palbociclib and Letrozole in Patients With Hormone Receptor Positive and Her2positive Metastatic Breast Cancer No ClinicalTrials.gov identifier reported
2016 Aspire Rheuma Derma Ibd Fecal Matrix Metallopeptidase 9 As A Novel Biomarker to Predict Mucosal Healing in Ulcerative Colitis No ClinicalTrials.gov identifier reported
2016 Aspire Rheuma Derma Ibd Novel Circulating Epithelial Cells As An Indicator of Disease Status and Cancer Risk No ClinicalTrials.gov identifier reported
2016 Aspire Rheuma Derma Ibd Prevalence Phenotype and Predictors of Lung Disease in Rheumatoid Arthritis No ClinicalTrials.gov identifier reported
2016 Aspire Rheuma Derma Ibd Quantitative and Qualitative Differences in Incident Coronary Atherosclerosis and Progression in Rheumatoid Arthritis Compared to Nonrheumatic Disease Controls No ClinicalTrials.gov identifier reported
2016 Aspire Sickle Cell Disease Acute Kidney Injuring During Sickle Cell Crises No ClinicalTrials.gov identifier reported
2016 Aspire Sickle Cell Disease Homebased Assessment of Patient Reported Outcome Measures Using A Smartphone App Platform A Feasibility Study No ClinicalTrials.gov identifier reported
2016 Aspire Sickle Cell Disease Use of Metformin As A Fetal Hemoglobin Inducer in Patients With Hemoglobinopathies No ClinicalTrials.gov identifier reported
2016 Aspire US Hemo Pharmacokinetictailored Approach to Prophylaxis in Hemophilia A Ptap Hemo No ClinicalTrials.gov identifier reported
2016-ELI-0313 A Phase III Randomized open label Study Evaluating the Safety and Efficacy of Apixaban in Subjects With Cancer Related Venous thromboembolism No ClinicalTrials.gov identifier reported
2016-Eli-0320 Personalized Risk Prediction of Stroke and Silent Brain Infarction Using Computational Fluid Dynamics No ClinicalTrials.gov identifier reported
2016-ELI-0351 Better Outcomes for Anticoagulation Treatment through Observation of Atrial Rhythm BOAT OAR No ClinicalTrials.gov identifier reported
2016-ELI-0362 Monotherapy Anticoagulation To expedite Home treatment of venous thromboembolism MATH VTE No ClinicalTrials.gov identifier reported
2016-ELO-0085 P2 Elo plus Rev for treatment of relapse progress while on Rev maintenance No ClinicalTrials.gov identifier reported
2016-L-0010 Adjuvant nivolumab and lirilumab in patients with relapsed, resectable squamous cell carcinoma of the head and neck No ClinicalTrials.gov identifier reported
2016-NIV-0413 A phase Ib study of concurrent intravenous and intrathecal nivolumab for patients with leptomeningeal disease (LMD) No ClinicalTrials.gov identifier reported
2016-NIV-0413 A phase Ib study of concurrent intravenous and intrathecal nivolumab for patients with leptomeningeal disease LMD No ClinicalTrials.gov identifier reported
2016-NIV-0415 Phase II study of front line therapy with nivolumab in and salvage nivolumab and ipilimumab patients with advanced renal cell carcinoma No ClinicalTrials.gov identifier reported
2016-NIV-0478 Phase II Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer No ClinicalTrials.gov identifier reported
2016-NIV-0489 Consolidative Ipi and Nivo with Thoracic Radiotherapy after Platinum Based Chemotherapy for Patients with ES-SCLC No ClinicalTrials.gov identifier reported
2016-NIV-0511 Ph II trial of concurrent nivo and radiation therapy in localized urothelial cancer of bladder [NUTRA] in patients who are not candidates for chemo No ClinicalTrials.gov identifier reported
2016-NIV-0511 Ph II trial of concurrent nivo and radiation therapy in localized urothelial cancer of bladder NUTRA in patients who are not candidates for chemo No ClinicalTrials.gov identifier reported
2016-NIV-0523 Phase I II study of nivolumab and axitinib in patients with advanced renal cell carcinoma No ClinicalTrials.gov identifier reported
2016-NIV-0523 Phase I/II study of nivolumab and axitinib in patients with advanced renal cell carcinoma No ClinicalTrials.gov identifier reported
2016-Niv-0525 A Pilot Trial of Ipilimumab With Nivolumab for Patients With Resected Stages Iiib/Iiic/ IV Melanoma No ClinicalTrials.gov identifier reported
2016-NIV-0532 PD-1 Immune Checkpoint Inhibition for the Prevention of Lung Cancer in Hi Risk Current and Former Smokers No ClinicalTrials.gov identifier reported
2016-NIV-0548 A ph II study of nivo comb with ipi for patients with advanced rare genitourinary tumors No ClinicalTrials.gov identifier reported
2016-NIV-0551 Pilot Study of Dual Checkpoint inhibition followed by immuno-chemoradiation in Patients with Resectable Gastric Adenocarcinoma No ClinicalTrials.gov identifier reported
2016-NIV-0558 Phase II study of nivo in combination with carboplatin plus pemetrexed in adult patients with ALK -positive or epidermal growth factor receptor EGFR -mutant NSCLC after progression on next-generation TKI No ClinicalTrials.gov identifier reported
2016-NIV-0573 OPTIMA II Trial - A study that evaluates the OPTIMA II clinical trial conducted in 2016 to assess treatment effectiveness in patients. (2016-NIV-0573 OPTIMA II Trial) No ClinicalTrials.gov identifier reported
2016-NIV-0614 Phase 2 study of the safety tolerability and efficacy of ipilumumab and nivolumab in combination with IMRT in HPVpositive OPSCC No ClinicalTrials.gov identifier reported
2016-NIV-0629 Predicting Outcome of Renal Cell Carcinoma Patients Based on Clinical, Molecular, Radiologic, and Histological Characteristics No ClinicalTrials.gov identifier reported
2016-NIV-0643 Phase II clinical trial of Nivolumab following Chemo-Radiation in localized Muscle-Invasive Bladder Cancer (NEXT) No ClinicalTrials.gov identifier reported
2016-NIV-0643 Phase II clinical trial of Nivolumab following Chemo-Radiation in localized Muscle-Invasive Bladder Cancer NEXT No ClinicalTrials.gov identifier reported
2016-NIV-0647 Phase II investigation of adjuvant nivolumab after salvage resection in pts treated with definitive chemotherapy and radiation No ClinicalTrials.gov identifier reported
2016-NIV-0665 Gem cis plus nivo as curative bladder-sparing tx for pts with DNA-damage resp mutant muscle-invasive bladder cancer No ClinicalTrials.gov identifier reported
2016-NIV-0668 Window-of-opportunity trial of nivolumab and tadalafil in patients with SSCHN No ClinicalTrials.gov identifier reported
2016-NIV-0669 A Pilot Study to Evaluate the Safety of Neoadj Nivo Alone or In Comb with Ipi for Cisplatin-Ineligible Pts with r (MIBC) No ClinicalTrials.gov identifier reported
2016-NIV-0671 Intraperitoneal Ipilimumab and Nivolumab in patients with peritoneal carcinomatosis due to gynecologic cancers No ClinicalTrials.gov identifier reported
2016-NIV-0673 Nivo therapy following partial HLA mismatched allogeneic bone marrow tx in child and YA with high risk recurrent or refractory sarcomas No ClinicalTrials.gov identifier reported
2016-NIV-0674 Eval the profiles of lymph subsets, autoantibodies, and ir gene exp in pts who dev nivo ipi therapy-related thyroiditis or hypophysitis No ClinicalTrials.gov identifier reported